Janssen Research & Development has submitted to the FDA a New Drug Application (NDA) for Invokamet XR, a once-daily therapy...
Janssen Pharmaceuticals announced the FDA has approved Invokamet XR�a once-daily, fixed-dose combination therapy of canagliflozin and metformin hydrochloride extended-release (XR)�for...
Janssen R&D has announced results of a Phase III, randomized study showing that the use of initial combination therapy of...